Princeton-based biosimulation company Certara Inc. has named a new president of integrated drug development, it announced Tuesday.
In his new role, Dr. Patrick F. Smith will lead the company’s global drug development services team, which serves clients across the entire drug development life cycle with biosimulation and quantitative approaches.
Smith succeeds Craig R. Rayner, who will be appointed Certara’s distinguished scientist. He will report to CEO William F. Feehery.
“I am excited to welcome Patrick as president of IDD,” Feehery said in a prepared statement. “With his extensive drug development experience, scientific thought leadership and close collaboration with clients, Patrick is the ideal leader to guide IDD in the next phase of growth.”
Smith joined Certara in 2016 after the company’s acquisition of d3 Medicine, which he founded.
